Skip to main content
Top
Published in: Journal of General Internal Medicine 4/2012

01-04-2012 | Reviews

Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches

Authors: Emaad M. Abdel-Rahman, MD, Lawand Saadulla, MD, W. Brian Reeves, MD, Alaa S. Awad, MD, MSc, FASN

Published in: Journal of General Internal Medicine | Issue 4/2012

Login to get access

Abstract

Diabetes mellitus is the leading cause of end stage renal disease and is responsible for more than 40% of all cases in the United States. Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, proteinuria/albuminuria reduction, interruption of the renin-angiotensin-aldosterone system through the use of angiotensin converting enzyme inhibitors and angiotensin type-1 receptor blockers, along with dietary modification and cholesterol lowering agents. However, the renal protection provided by these therapeutic modalities is incomplete. More effective approaches are urgently needed. This review highlights the available standard therapeutic approaches to manage progressive diabetic nephropathy, including markers for early diagnosis of diabetic nephropathy. Furthermore, we will discuss emerging strategies such as PPAR-gamma agonists, Endothelin blockers, vitamin D activation and inflammation modulation. Finally, we will summarize the recommendations of these interventions for the primary care practitioner.
Literature
1.
go back to reference USRDS TUSRDS. Annual Data Report. Bethesda: The National Institutes of Diabetes and Digestive and Kidney Diseases; 2005. USRDS TUSRDS. Annual Data Report. Bethesda: The National Institutes of Diabetes and Digestive and Kidney Diseases; 2005.
2.
go back to reference Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42:617–22.PubMedCrossRef Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42:617–22.PubMedCrossRef
3.
go back to reference Adler S. Diabetic nephropathy: linking histology, cell biology, and genetics. Kidney Int. 2004;66:2095–106.PubMedCrossRef Adler S. Diabetic nephropathy: linking histology, cell biology, and genetics. Kidney Int. 2004;66:2095–106.PubMedCrossRef
4.
go back to reference Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311:89–93.PubMedCrossRef Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311:89–93.PubMedCrossRef
5.
go back to reference Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000;49:1399–408.PubMedCrossRef Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000;49:1399–408.PubMedCrossRef
6.
go back to reference Caramori ML, Fioretto P, Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol. 2006;17:339–52.PubMedCrossRef Caramori ML, Fioretto P, Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol. 2006;17:339–52.PubMedCrossRef
7.
go back to reference Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes. 2003;52:1036–40.PubMedCrossRef Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes. 2003;52:1036–40.PubMedCrossRef
8.
go back to reference Zerbini G, Bonfanti R, Meschi F, et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes. 2006;55:2620–5.PubMedCrossRef Zerbini G, Bonfanti R, Meschi F, et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes. 2006;55:2620–5.PubMedCrossRef
9.
go back to reference Ito Y, Aten J, Bende RJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 1998;53:853–61.PubMedCrossRef Ito Y, Aten J, Bende RJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 1998;53:853–61.PubMedCrossRef
10.
go back to reference Nguyen TQ, Tarnow L, Andersen S, et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29:83–8.PubMedCrossRef Nguyen TQ, Tarnow L, Andersen S, et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29:83–8.PubMedCrossRef
11.
go back to reference Langham RG, Kelly DJ, Gow RM, et al. Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition. Diabetes Care. 2006;29:2670–5.PubMedCrossRef Langham RG, Kelly DJ, Gow RM, et al. Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition. Diabetes Care. 2006;29:2670–5.PubMedCrossRef
12.
go back to reference Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003;64:1208–13.PubMedCrossRef Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003;64:1208–13.PubMedCrossRef
13.
go back to reference Nakamura T, Ushiyama C, Suzuki S, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 2000;15:1379–83.PubMedCrossRef Nakamura T, Ushiyama C, Suzuki S, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 2000;15:1379–83.PubMedCrossRef
14.
go back to reference Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:337–44.PubMedCrossRef Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:337–44.PubMedCrossRef
15.
go back to reference Vaidya VS, Niewczas MA, Ficociello LH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase. Kidney Int. 2011;79:464–70.PubMedCrossRef Vaidya VS, Niewczas MA, Ficociello LH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase. Kidney Int. 2011;79:464–70.PubMedCrossRef
16.
go back to reference The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–986. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977986.
17.
go back to reference Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342:381–389. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342:381389.
18.
go back to reference Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–2167. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:21592167.
19.
go back to reference Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.PubMedCrossRef Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.PubMedCrossRef
20.
go back to reference Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.PubMedCrossRef Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.PubMedCrossRef
21.
go back to reference Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.PubMedCrossRef Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.PubMedCrossRef
22.
go back to reference Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837853.
23.
go back to reference Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRef Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRef
24.
go back to reference Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419–30.PubMedCrossRef Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419–30.PubMedCrossRef
25.
go back to reference Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.PubMedCrossRef Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.PubMedCrossRef
26.
go back to reference Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61:827–37.PubMed Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61:827–37.PubMed
27.
go back to reference Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2002. Clin Transplant. 2002;2002:41–77. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2002. Clin Transplant. 2002;2002:41–77.
28.
go back to reference Coppelli A, Giannarelli R, Vistoli F, et al. The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care. 2005;28:1366–70.PubMedCrossRef Coppelli A, Giannarelli R, Vistoli F, et al. The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care. 2005;28:1366–70.PubMedCrossRef
29.
go back to reference Bilous RW, Mauer SM, Sutherland DE, et al. The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. N Engl J Med. 1989;321:80–5.PubMedCrossRef Bilous RW, Mauer SM, Sutherland DE, et al. The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. N Engl J Med. 1989;321:80–5.PubMedCrossRef
30.
go back to reference Fioretto P, Mauer SM, Bilous RW, et al. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet. 1993;342:1193–6.PubMedCrossRef Fioretto P, Mauer SM, Bilous RW, et al. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet. 1993;342:1193–6.PubMedCrossRef
31.
go back to reference Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69–75.PubMedCrossRef Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69–75.PubMedCrossRef
32.
go back to reference Huang ES, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med. 2008;149:11–9.PubMed Huang ES, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med. 2008;149:11–9.PubMed
33.
go back to reference Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed). 1982;285:685–8.CrossRef Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed). 1982;285:685–8.CrossRef
34.
go back to reference Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086–97.PubMedCrossRef Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086–97.PubMedCrossRef
35.
go back to reference Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703–713. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703713.
36.
go back to reference Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ. 1998;317:720–726. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ. 1998;317:720726.
37.
go back to reference Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.PubMedCrossRef Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.PubMedCrossRef
38.
go back to reference de Galan BE, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883–92.PubMedCrossRef de Galan BE, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883–92.PubMedCrossRef
39.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52.PubMedCrossRef
40.
go back to reference Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl 1):S4-S36. Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl 1):S4-S36.
41.
go back to reference K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1-290. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1-290.
42.
go back to reference Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010.
43.
go back to reference Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3–10.PubMedCrossRef Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3–10.PubMedCrossRef
44.
go back to reference Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346:1080–4.PubMedCrossRef Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346:1080–4.PubMedCrossRef
45.
go back to reference Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129–38.PubMed Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129–38.PubMed
46.
go back to reference Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) trial. Diabetologia. 1996;39:1646–54.PubMedCrossRef Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) trial. Diabetologia. 1996;39:1646–54.PubMedCrossRef
47.
go back to reference Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.PubMedCrossRef Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.PubMedCrossRef
48.
go back to reference Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control and the progression of chronic renal disease. N Engl J Med. 1994;330:877–84.PubMedCrossRef Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control and the progression of chronic renal disease. N Engl J Med. 1994;330:877–84.PubMedCrossRef
49.
go back to reference Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–31.PubMedCrossRef Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–31.PubMedCrossRef
50.
go back to reference Nilsson PM, Cederholm J. Diabetes, hypertension, and outcome studies: overview 2010. Diabetes Care. 2011;34(Suppl 2):S109–13.PubMedCrossRef Nilsson PM, Cederholm J. Diabetes, hypertension, and outcome studies: overview 2010. Diabetes Care. 2011;34(Suppl 2):S109–13.PubMedCrossRef
51.
go back to reference Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S80–2.PubMed Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S80–2.PubMed
52.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.PubMedCrossRef
53.
go back to reference Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.PubMedCrossRef Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.PubMedCrossRef
54.
go back to reference Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8.PubMedCrossRef Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8.PubMedCrossRef
55.
go back to reference Cederholm J, Gudbjornsdottir S, Eliasson B, et al. Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register. J Hypertens. 2010;28:2026–35.PubMed Cederholm J, Gudbjornsdottir S, Eliasson B, et al. Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register. J Hypertens. 2010;28:2026–35.PubMed
56.
57.
go back to reference Melchior WR, Bindlish V, Jaber LA. Angiotensin-converting enzyme inhibitors in diabetic nephropathy. Ann Pharmacother. 1993;27:344–50.PubMed Melchior WR, Bindlish V, Jaber LA. Angiotensin-converting enzyme inhibitors in diabetic nephropathy. Ann Pharmacother. 1993;27:344–50.PubMed
58.
go back to reference Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.PubMedCrossRef Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.PubMedCrossRef
59.
go back to reference Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25:1921–6.PubMedCrossRef Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25:1921–6.PubMedCrossRef
60.
go back to reference Burgess E, Muirhead N, Rene de Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20:893–900.PubMedCrossRef Burgess E, Muirhead N, Rene de Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20:893–900.PubMedCrossRef
61.
go back to reference Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30–48.PubMed Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30–48.PubMed
62.
go back to reference Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.PubMedCrossRef Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.PubMedCrossRef
63.
go back to reference Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997;349:1787–1792. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997;349:17871792.
64.
go back to reference Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982–8.PubMed Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982–8.PubMed
65.
go back to reference Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–64.PubMed Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–64.PubMed
66.
go back to reference Ravid M, Savin H, Jutrin I, et al. Long-term stabilization of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577–81.PubMed Ravid M, Savin H, Jutrin I, et al. Long-term stabilization of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577–81.PubMed
67.
go back to reference Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000;57:601–6.PubMedCrossRef Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000;57:601–6.PubMedCrossRef
68.
go back to reference Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.PubMedCrossRef Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.PubMedCrossRef
69.
go back to reference Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.PubMedCrossRef Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.PubMedCrossRef
70.
go back to reference Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.PubMedCrossRef Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.PubMedCrossRef
71.
go back to reference Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.PubMedCrossRef Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.PubMedCrossRef
72.
go back to reference van den Meiracker AH, AJ Man in 't Veld, Admiraal PJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10:803–12.PubMed van den Meiracker AH, AJ Man in 't Veld, Admiraal PJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10:803–12.PubMed
73.
go back to reference Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486–92.PubMedCrossRef Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486–92.PubMedCrossRef
74.
go back to reference Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med. 2008;358:2503–5.PubMedCrossRef Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med. 2008;358:2503–5.PubMedCrossRef
75.
go back to reference Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1–8.PubMedCrossRef Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1–8.PubMedCrossRef
76.
go back to reference Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126–33.PubMedCrossRef Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126–33.PubMedCrossRef
77.
go back to reference Azizi M, Menard J, Bissery A, et al. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol. 2007;2:947–55.PubMedCrossRef Azizi M, Menard J, Bissery A, et al. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol. 2007;2:947–55.PubMedCrossRef
78.
go back to reference Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221–9.PubMedCrossRef Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221–9.PubMedCrossRef
79.
go back to reference Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11–20.PubMedCrossRef Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11–20.PubMedCrossRef
80.
go back to reference Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190–8.PubMedCrossRef Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190–8.PubMedCrossRef
81.
go back to reference Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–46.PubMedCrossRef Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–46.PubMedCrossRef
82.
go back to reference Ustundag A, Tugrul A, Ustundag S, et al. The effects of spironolactone on nephron function in patients with diabetic nephropathy. Ren Fail. 2008;30:982–91.PubMedCrossRef Ustundag A, Tugrul A, Ustundag S, et al. The effects of spironolactone on nephron function in patients with diabetic nephropathy. Ren Fail. 2008;30:982–91.PubMedCrossRef
83.
go back to reference Saklayen MG, Gyebi LK, Tasosa J, et al. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med. 2008;56:714–9.PubMed Saklayen MG, Gyebi LK, Tasosa J, et al. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med. 2008;56:714–9.PubMed
84.
go back to reference Kang YS, Ko GJ, Lee MH, et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant. 2009;24:73–84.PubMedCrossRef Kang YS, Ko GJ, Lee MH, et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant. 2009;24:73–84.PubMedCrossRef
85.
go back to reference Epstein M, Buckalew VJ, Martinez F, Altamirano J, Roniker B, Kleiman J, Krause S, Eplerenone 021 Investigators. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens. 2002;15:24A.CrossRef Epstein M, Buckalew VJ, Martinez F, Altamirano J, Roniker B, Kleiman J, Krause S, Eplerenone 021 Investigators. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens. 2002;15:24A.CrossRef
86.
go back to reference Rachmani R, Slavachevsky I, Amit M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med. 2004;21:471–5.PubMedCrossRef Rachmani R, Slavachevsky I, Amit M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med. 2004;21:471–5.PubMedCrossRef
87.
go back to reference Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64–8.PubMedCrossRef Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64–8.PubMedCrossRef
88.
go back to reference Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106–12.PubMedCrossRef Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106–12.PubMedCrossRef
89.
go back to reference Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536–42.PubMed Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536–42.PubMed
90.
go back to reference Ogawa S, Takeuchi K, Mori T, et al. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol. 2006;33:477–9.PubMedCrossRef Ogawa S, Takeuchi K, Mori T, et al. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol. 2006;33:477–9.PubMedCrossRef
91.
go back to reference Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829–36.PubMedCrossRef Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829–36.PubMedCrossRef
92.
go back to reference Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005;46:45–51.PubMedCrossRef Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005;46:45–51.PubMedCrossRef
93.
go back to reference Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641–50.PubMedCrossRef Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641–50.PubMedCrossRef
94.
go back to reference Parving HH, Tarnow L, Rossing P. Renal protection in diabetes: an emerging role for calcium antagonists. J Hypertens Suppl. 1996;14:S21–5.PubMedCrossRef Parving HH, Tarnow L, Rossing P. Renal protection in diabetes: an emerging role for calcium antagonists. J Hypertens Suppl. 1996;14:S21–5.PubMedCrossRef
95.
go back to reference Mimran A, Insua A, Ribstein J, et al. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care. 1988;11:850–3.PubMedCrossRef Mimran A, Insua A, Ribstein J, et al. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care. 1988;11:850–3.PubMedCrossRef
96.
go back to reference Baba T, Murabayashi S, Takebe K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial. Diabetologia. 1989;32:40–4.PubMed Baba T, Murabayashi S, Takebe K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial. Diabetologia. 1989;32:40–4.PubMed
97.
go back to reference Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. BMJ. 1991;302:210–216. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. BMJ. 1991;302:210216.
98.
go back to reference Mosconi L, Ruggenenti P, Perna A, et al. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int Suppl. 1996;55:S91–3.PubMed Mosconi L, Ruggenenti P, Perna A, et al. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int Suppl. 1996;55:S91–3.PubMed
99.
go back to reference Crepaldi G, Carraro A, Brocco E, et al. Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist. Acta Diabetol. 1995;32:203–8.PubMedCrossRef Crepaldi G, Carraro A, Brocco E, et al. Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist. Acta Diabetol. 1995;32:203–8.PubMedCrossRef
100.
go back to reference Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996;45:216–22.PubMedCrossRef Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996;45:216–22.PubMedCrossRef
101.
go back to reference Corradi LLP, Pasotti C, Zoppi A, Preti P, Lazzari P, et al. Effect of amlopidine vs. fosinopril on microalbuminuria in elderly hypertensive patients with type II diabetes. Am J Hypertens. 1996;9:152A.CrossRef Corradi LLP, Pasotti C, Zoppi A, Preti P, Lazzari P, et al. Effect of amlopidine vs. fosinopril on microalbuminuria in elderly hypertensive patients with type II diabetes. Am J Hypertens. 1996;9:152A.CrossRef
102.
go back to reference Jungmann EHT, Malanyn M, Mortasawi N, Schererich J, Usadel KH. Comparative study on renal effects of nitrendipine vs. enalapril in microalbuminuric patients with type 1 diabetes mellitus. Diabetologia. 1992;35:A149. Jungmann EHT, Malanyn M, Mortasawi N, Schererich J, Usadel KH. Comparative study on renal effects of nitrendipine vs. enalapril in microalbuminuric patients with type 1 diabetes mellitus. Diabetologia. 1992;35:A149.
103.
go back to reference Stornello M, Valvo EV, Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol. 1989;14:851–5.PubMedCrossRef Stornello M, Valvo EV, Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol. 1989;14:851–5.PubMedCrossRef
104.
go back to reference Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990;112:707–8.PubMed Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990;112:707–8.PubMed
105.
go back to reference Romero R, Salinas I, Lucas A, et al. Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. Diabetes Res Clin Pract. 1992;17:191–8.PubMedCrossRef Romero R, Salinas I, Lucas A, et al. Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. Diabetes Res Clin Pract. 1992;17:191–8.PubMedCrossRef
106.
go back to reference Ferder L, Daccordi H, Martello M, et al. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension. 1992;19:II237–42.PubMed Ferder L, Daccordi H, Martello M, et al. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension. 1992;19:II237–42.PubMed
107.
go back to reference Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992;41:912–9.PubMedCrossRef Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992;41:912–9.PubMedCrossRef
108.
go back to reference Norgaard K, Jensen T, Christensen P, et al. A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Press. 1993;2:301–8.PubMedCrossRef Norgaard K, Jensen T, Christensen P, et al. A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Press. 1993;2:301–8.PubMedCrossRef
109.
go back to reference Rossing P, Tarnow L, Boelskifte S, et al. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes. 1997;46:481–7.PubMedCrossRef Rossing P, Tarnow L, Boelskifte S, et al. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes. 1997;46:481–7.PubMedCrossRef
110.
go back to reference Corradi LFR, Zoppi A, Lusardi P, Preti P, Lazzari P, et al. Long term effects of ramipril and nitrendipine on albuminuria in diabetic hypertensive patients with impaired renal function. Am J Hypertens. 1996;9:151A.CrossRef Corradi LFR, Zoppi A, Lusardi P, Preti P, Lazzari P, et al. Long term effects of ramipril and nitrendipine on albuminuria in diabetic hypertensive patients with impaired renal function. Am J Hypertens. 1996;9:151A.CrossRef
111.
go back to reference Bakris GL CJ, Vicknair N, Leurgans S. Effect of nondihydropyridine calcium antagonists (NDCAs) on progression of nephropathy from noninsulin dependent diabetes (NIDDM). J Am Soc Nephrol. 1995;6:446. Bakris GL CJ, Vicknair N, Leurgans S. Effect of nondihydropyridine calcium antagonists (NDCAs) on progression of nephropathy from noninsulin dependent diabetes (NIDDM). J Am Soc Nephrol. 1995;6:446.
112.
go back to reference O'Donnell MJ, Rowe B, Lawson N, Horton A, Gide OHV, Barnett AH. Comparative study of lisinopril and nifedipine in treatment of diabetic patients with hypertension and macroproteinuria. Diabetes. 1991;40:505A. O'Donnell MJ, Rowe B, Lawson N, Horton A, Gide OHV, Barnett AH. Comparative study of lisinopril and nifedipine in treatment of diabetic patients with hypertension and macroproteinuria. Diabetes. 1991;40:505A.
113.
go back to reference Holdaas H, Hartmann A, Lien MG, Nielsen L, Fauchald T, Jervell J, et al. Lisinopril but not nifedipine reduces urinary albumin excretion in diabetic nephropathy. Kidney Int. 1990;37:239. Holdaas H, Hartmann A, Lien MG, Nielsen L, Fauchald T, Jervell J, et al. Lisinopril but not nifedipine reduces urinary albumin excretion in diabetic nephropathy. Kidney Int. 1990;37:239.
114.
go back to reference Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28.PubMedCrossRef Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28.PubMedCrossRef
115.
go back to reference Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173–81.PubMedCrossRef Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173–81.PubMedCrossRef
116.
go back to reference Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991–2002.PubMedCrossRef Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991–2002.PubMedCrossRef
117.
go back to reference Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51:2–15.PubMedCrossRef Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51:2–15.PubMedCrossRef
118.
go back to reference Kloke HJ, Branten AJ, Huysmans FT, et al. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int. 1998;53:1559–73.PubMedCrossRef Kloke HJ, Branten AJ, Huysmans FT, et al. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int. 1998;53:1559–73.PubMedCrossRef
119.
go back to reference Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963–74.PubMed Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963–74.PubMed
120.
go back to reference Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641–50.PubMedCrossRef Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641–50.PubMedCrossRef
121.
go back to reference Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997;29:744–50.PubMed Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997;29:744–50.PubMed
122.
go back to reference Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117–24.PubMedCrossRef Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117–24.PubMedCrossRef
123.
go back to reference Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis. 1999;33:1004–10.PubMedCrossRef Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis. 1999;33:1004–10.PubMedCrossRef
124.
go back to reference Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1997;46:1182–8.PubMedCrossRef Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1997;46:1182–8.PubMedCrossRef
125.
go back to reference Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317:713–720. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317:713720.
126.
go back to reference Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004;22:1613–22.PubMedCrossRef Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004;22:1613–22.PubMedCrossRef
127.
go back to reference Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008;73:1303–9.PubMedCrossRef Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008;73:1303–9.PubMedCrossRef
128.
go back to reference National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41:S1–92. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41:S1–92.
129.
go back to reference O'Brien T, Nguyen TT, Zimmerman BR. Hyperlipidemia and diabetes mellitus. Mayo Clin Proc. 1998;73:969–76.PubMedCrossRef O'Brien T, Nguyen TT, Zimmerman BR. Hyperlipidemia and diabetes mellitus. Mayo Clin Proc. 1998;73:969–76.PubMedCrossRef
130.
go back to reference Ginsberg HN. REVIEW: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2006;91:383–92.PubMedCrossRef Ginsberg HN. REVIEW: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2006;91:383–92.PubMedCrossRef
131.
go back to reference Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820–5.PubMedCrossRef Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820–5.PubMedCrossRef
132.
go back to reference Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.PubMedCrossRef Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.PubMedCrossRef
133.
go back to reference Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:29983007.
134.
go back to reference MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:722.
135.
go back to reference Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.PubMedCrossRef Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.PubMedCrossRef
136.
go back to reference Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.PubMedCrossRef Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.PubMedCrossRef
137.
go back to reference Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151–7.PubMedCrossRef Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151–7.PubMedCrossRef
138.
go back to reference Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140:650–8.PubMed Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140:650–8.PubMed
139.
go back to reference Tonelli M, Moye L, Sacks FM, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138:98–104.PubMed Tonelli M, Moye L, Sacks FM, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138:98–104.PubMed
140.
go back to reference Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.PubMedCrossRef Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.PubMedCrossRef
141.
go back to reference Jones C, Roderick P, Harris S, et al. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant. 2006;21:2133–43.PubMedCrossRef Jones C, Roderick P, Harris S, et al. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant. 2006;21:2133–43.PubMedCrossRef
142.
go back to reference Chan MR, Dall AT, Fletcher KE, et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med. 2007;120:1063–70.PubMedCrossRef Chan MR, Dall AT, Fletcher KE, et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med. 2007;120:1063–70.PubMedCrossRef
143.
go back to reference Avorn J, Bohn RL, Levy E, et al. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med. 2002;162:2002–6.PubMedCrossRef Avorn J, Bohn RL, Levy E, et al. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med. 2002;162:2002–6.PubMedCrossRef
144.
go back to reference Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137:479–86.PubMed Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137:479–86.PubMed
145.
go back to reference Ghossein C, Serrano A, Rammohan M, et al. The role of comprehensive renal clinic in chronic kidney disease stabilization and management: the Northwestern experience. Semin Nephrol. 2002;22:526–32.PubMed Ghossein C, Serrano A, Rammohan M, et al. The role of comprehensive renal clinic in chronic kidney disease stabilization and management: the Northwestern experience. Semin Nephrol. 2002;22:526–32.PubMed
146.
go back to reference Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001;56:265–94.PubMedCrossRef Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001;56:265–94.PubMedCrossRef
147.
go back to reference Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27:1349–57.PubMedCrossRef Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27:1349–57.PubMedCrossRef
148.
go back to reference Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004;27:484–90.PubMedCrossRef Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004;27:484–90.PubMedCrossRef
149.
go back to reference Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–6.PubMedCrossRef Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–6.PubMedCrossRef
150.
go back to reference Harte A, McTernan P, Chetty R, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation. 2005;111:1954–61.PubMedCrossRef Harte A, McTernan P, Chetty R, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation. 2005;111:1954–61.PubMedCrossRef
151.
go back to reference Takeda K, Ichiki T, Tokunou T, et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834–9.PubMed Takeda K, Ichiki T, Tokunou T, et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834–9.PubMed
152.
go back to reference Sugawara A, Takeuchi K, Uruno A, et al. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens Res. 2001;24:229–33.PubMedCrossRef Sugawara A, Takeuchi K, Uruno A, et al. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens Res. 2001;24:229–33.PubMedCrossRef
153.
go back to reference Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000;14:250–4.PubMedCrossRef Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000;14:250–4.PubMedCrossRef
154.
go back to reference Ruan XZ, Moorhead JF, Fernando R, et al. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol. 2003;14:593–600.PubMedCrossRef Ruan XZ, Moorhead JF, Fernando R, et al. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol. 2003;14:593–600.PubMedCrossRef
155.
go back to reference Wu J, Zhang Y, Wang N, et al. Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells. Am J Physiol Renal Physiol. 2004;287:F886–95.PubMedCrossRef Wu J, Zhang Y, Wang N, et al. Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells. Am J Physiol Renal Physiol. 2004;287:F886–95.PubMedCrossRef
156.
go back to reference Chana RS, Lewington AJ, Brunskill NJ. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists. Kidney Int. 2004;65:2081–90.PubMedCrossRef Chana RS, Lewington AJ, Brunskill NJ. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists. Kidney Int. 2004;65:2081–90.PubMedCrossRef
157.
go back to reference Panchapakesan U, Pollock CA, Chen XM. The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells. Am J Physiol Renal Physiol. 2004;287:F528–34.PubMedCrossRef Panchapakesan U, Pollock CA, Chen XM. The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells. Am J Physiol Renal Physiol. 2004;287:F528–34.PubMedCrossRef
158.
go back to reference Yoshimoto T, Naruse M, Nishikawa M, et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol. 1997;272:E989–96.PubMed Yoshimoto T, Naruse M, Nishikawa M, et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol. 1997;272:E989–96.PubMed
159.
go back to reference Buckingham RE, Al-Barazanji KA, Toseland CD, et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes. 1998;47:1326–34.PubMedCrossRef Buckingham RE, Al-Barazanji KA, Toseland CD, et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes. 1998;47:1326–34.PubMedCrossRef
160.
go back to reference Yamashita H, Nagai Y, Takamura T, et al. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism. 2002;51:403–8.PubMedCrossRef Yamashita H, Nagai Y, Takamura T, et al. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism. 2002;51:403–8.PubMedCrossRef
161.
go back to reference Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes. 2000;49:1022–32.PubMedCrossRef Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes. 2000;49:1022–32.PubMedCrossRef
162.
go back to reference Baylis C, Atzpodien EA, Freshour G, et al. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther. 2003;307:854–60.PubMedCrossRef Baylis C, Atzpodien EA, Freshour G, et al. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther. 2003;307:854–60.PubMedCrossRef
163.
go back to reference Yoshida K, Kohzuki M, Xu HL, et al. Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure. J Hypertens. 2001;19:503–10.PubMedCrossRef Yoshida K, Kohzuki M, Xu HL, et al. Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure. J Hypertens. 2001;19:503–10.PubMedCrossRef
164.
go back to reference Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 1998;21:2135–9.PubMedCrossRef Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 1998;21:2135–9.PubMedCrossRef
165.
go back to reference Nakamura T, Ushiyama C, Suzuki S, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med. 2001;18:308–13.PubMedCrossRef Nakamura T, Ushiyama C, Suzuki S, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med. 2001;18:308–13.PubMedCrossRef
166.
go back to reference Nakamura T, Ushiyama C, Osada S, et al. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism. 2001;50:1193–6.PubMedCrossRef Nakamura T, Ushiyama C, Osada S, et al. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism. 2001;50:1193–6.PubMedCrossRef
167.
go back to reference Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med. 2004;116:230–5.PubMedCrossRef Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med. 2004;116:230–5.PubMedCrossRef
168.
go back to reference Yanagawa T, Araki A, Sasamoto K, et al. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism. 2004;53:353–7.PubMedCrossRef Yanagawa T, Araki A, Sasamoto K, et al. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism. 2004;53:353–7.PubMedCrossRef
169.
go back to reference Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27:141–7.PubMedCrossRef Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27:141–7.PubMedCrossRef
170.
go back to reference Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89:6068–76.PubMedCrossRef Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89:6068–76.PubMedCrossRef
171.
go back to reference Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int. 2005;68:285–92.PubMedCrossRef Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int. 2005;68:285–92.PubMedCrossRef
172.
go back to reference Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280–8.PubMedCrossRef Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280–8.PubMedCrossRef
173.
go back to reference Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens. 2005;18:227–34.PubMedCrossRef Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens. 2005;18:227–34.PubMedCrossRef
174.
go back to reference Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes. 2005;54:2206–11.PubMedCrossRef Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes. 2005;54:2206–11.PubMedCrossRef
175.
go back to reference Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006;24:2047–55.PubMedCrossRef Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006;24:2047–55.PubMedCrossRef
176.
go back to reference Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411–8.PubMedCrossRef Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411–8.PubMedCrossRef
177.
go back to reference Burns KD. The emerging role of angiotensin-converting enzyme-2 in the kidney. Curr Opin Nephrol Hypertens. 2007;16:116–21.PubMedCrossRef Burns KD. The emerging role of angiotensin-converting enzyme-2 in the kidney. Curr Opin Nephrol Hypertens. 2007;16:116–21.PubMedCrossRef
178.
go back to reference Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383:45–51.PubMedCrossRef Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383:45–51.PubMedCrossRef
179.
go back to reference Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1–7) on isolated rabbit afferent arterioles. Hypertension. 2002;39:799–802.PubMedCrossRef Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1–7) on isolated rabbit afferent arterioles. Hypertension. 2002;39:799–802.PubMedCrossRef
180.
go back to reference Ye M, Wysocki J, William J, et al. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17:3067–75.PubMedCrossRef Ye M, Wysocki J, William J, et al. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17:3067–75.PubMedCrossRef
181.
go back to reference Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–5.PubMedCrossRef Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–5.PubMedCrossRef
182.
go back to reference Minchenko AG, Stevens MJ, White L, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J. 2003;17:1514–6.PubMed Minchenko AG, Stevens MJ, White L, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J. 2003;17:1514–6.PubMed
183.
go back to reference Hocher B, Lun A, Priem F, et al. Renal endothelin system in diabetes: comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S492–5.PubMedCrossRef Hocher B, Lun A, Priem F, et al. Renal endothelin system in diabetes: comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S492–5.PubMedCrossRef
184.
185.
go back to reference Benigni A. Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies. Curr Opin Nephrol Hypertens. 1995;4:349–53.PubMedCrossRef Benigni A. Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies. Curr Opin Nephrol Hypertens. 1995;4:349–53.PubMedCrossRef
186.
go back to reference Kohan DE. Autocrine role of endothelin in rat inner medullary collecting duct: inhibition of AVP-induced cAMP accumulation. J Cardiovasc Pharmacol. 1993;22(Suppl 8):S174–9.PubMedCrossRef Kohan DE. Autocrine role of endothelin in rat inner medullary collecting duct: inhibition of AVP-induced cAMP accumulation. J Cardiovasc Pharmacol. 1993;22(Suppl 8):S174–9.PubMedCrossRef
187.
go back to reference Ahn D, Ge Y, Stricklett PK, et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest. 2004;114:504–11.PubMed Ahn D, Ge Y, Stricklett PK, et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest. 2004;114:504–11.PubMed
188.
go back to reference Lee YJ, Shin SJ, Tsai JH. Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diabetes Care. 1994;17:263–6.PubMedCrossRef Lee YJ, Shin SJ, Tsai JH. Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diabetes Care. 1994;17:263–6.PubMedCrossRef
189.
go back to reference De Mattia G, Cassone-Faldetta M, Bellini C, et al. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertens. 1998;11:983–8.PubMedCrossRef De Mattia G, Cassone-Faldetta M, Bellini C, et al. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertens. 1998;11:983–8.PubMedCrossRef
190.
go back to reference Ak G, Buyukberber S, Sevinc A, et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus. J Diabetes Complications. 2001;15:150–7.PubMedCrossRef Ak G, Buyukberber S, Sevinc A, et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus. J Diabetes Complications. 2001;15:150–7.PubMedCrossRef
191.
go back to reference Candido R, Allen TJ. Haemodynamics in microvascular complications in type 1 diabetes. Diabetes Metab Res Rev. 2002;18:286–304.PubMedCrossRef Candido R, Allen TJ. Haemodynamics in microvascular complications in type 1 diabetes. Diabetes Metab Res Rev. 2002;18:286–304.PubMedCrossRef
192.
go back to reference Zanatta CM, Gerchman F, Burttet L, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;80:299–304.PubMedCrossRef Zanatta CM, Gerchman F, Burttet L, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;80:299–304.PubMedCrossRef
193.
go back to reference Chade AR, Krier JD, Textor SC, et al. Endothelin-a receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. J Am Soc Nephrol. 2006;17:3394–403.PubMedCrossRef Chade AR, Krier JD, Textor SC, et al. Endothelin-a receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. J Am Soc Nephrol. 2006;17:3394–403.PubMedCrossRef
194.
go back to reference Sasser JM, Sullivan JC, Hobbs JL, et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol. 2007;18:143–54.PubMedCrossRef Sasser JM, Sullivan JC, Hobbs JL, et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol. 2007;18:143–54.PubMedCrossRef
195.
go back to reference Thone-Reinke C, Simon K, Richter CM, et al. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol. 2004;44(Suppl 1):S76–9.PubMedCrossRef Thone-Reinke C, Simon K, Richter CM, et al. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol. 2004;44(Suppl 1):S76–9.PubMedCrossRef
196.
go back to reference Sugimoto K, Fujimori A, Yuyama H, et al. Renal protective effect of YM598, a selective endothelin type A receptor antagonist. J Cardiovasc Pharmacol. 2004;44(Suppl 1):S451–4.PubMedCrossRef Sugimoto K, Fujimori A, Yuyama H, et al. Renal protective effect of YM598, a selective endothelin type A receptor antagonist. J Cardiovasc Pharmacol. 2004;44(Suppl 1):S451–4.PubMedCrossRef
197.
go back to reference Gross ML, Ritz E, Schoof A, et al. Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Investig. 2003;83:1267–77.PubMedCrossRef Gross ML, Ritz E, Schoof A, et al. Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Investig. 2003;83:1267–77.PubMedCrossRef
198.
go back to reference Cosenzi A, Bernobich E, Trevisan R, et al. Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol. 2003;42:752–6.PubMedCrossRef Cosenzi A, Bernobich E, Trevisan R, et al. Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol. 2003;42:752–6.PubMedCrossRef
199.
go back to reference Honing ML, Hijmering ML, Ballard DE, et al. ABT-627, a selective eta-receptor antagonist, reduces proteinuria in patients with diabetes mellitus. In: Regulation of Vascular Tone in Humans by Endothelium-Derived Mediators. Utrecht, Netherlands: Elinkwijk BV; 2000;89–102 Honing ML, Hijmering ML, Ballard DE, et al. ABT-627, a selective eta-receptor antagonist, reduces proteinuria in patients with diabetes mellitus. In: Regulation of Vascular Tone in Humans by Endothelium-Derived Mediators. Utrecht, Netherlands: Elinkwijk BV; 2000;89–102
200.
go back to reference Wenzel RR et al. The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. ASN Renal Week 2005. Wenzel RR et al. The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. ASN Renal Week 2005.
201.
go back to reference Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21:527–35.PubMedCrossRef Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21:527–35.PubMedCrossRef
202.
go back to reference Glomb MA, Pfahler C. Amides are novel protein modifications formed by physiological sugars. J Biol Chem. 2001;276:41638–47.PubMedCrossRef Glomb MA, Pfahler C. Amides are novel protein modifications formed by physiological sugars. J Biol Chem. 2001;276:41638–47.PubMedCrossRef
203.
go back to reference Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315–21.PubMedCrossRef Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315–21.PubMedCrossRef
204.
go back to reference Abdel-Rahman E, Bolton WK. Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs. 2002;11:565–74.PubMedCrossRef Abdel-Rahman E, Bolton WK. Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs. 2002;11:565–74.PubMedCrossRef
205.
go back to reference Freedman BI, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials. 1999;20:493–510.PubMedCrossRef Freedman BI, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials. 1999;20:493–510.PubMedCrossRef
206.
go back to reference Williams ME. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr Diab Rep. 2004;4:441–6.PubMedCrossRef Williams ME. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr Diab Rep. 2004;4:441–6.PubMedCrossRef
207.
go back to reference Williams ME. A phase 2 clinical trial of pyridoxamine (Pyridorin) in type 1 and type 2 diabetic patients with overt nephropathy (PYR-206). J Am Soc Nephrol. 2003;2003:7A. Williams ME. A phase 2 clinical trial of pyridoxamine (Pyridorin) in type 1 and type 2 diabetic patients with overt nephropathy (PYR-206). J Am Soc Nephrol. 2003;2003:7A.
208.
go back to reference Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104:1464–70.PubMedCrossRef Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104:1464–70.PubMedCrossRef
209.
go back to reference Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 2003;419:89–96.PubMedCrossRef Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 2003;419:89–96.PubMedCrossRef
210.
go back to reference de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376:1543–51.PubMedCrossRef de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376:1543–51.PubMedCrossRef
211.
go back to reference Pergola PE, Krauth M, Huff JW, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol. 2011;33:469–76.PubMedCrossRef Pergola PE, Krauth M, Huff JW, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol. 2011;33:469–76.PubMedCrossRef
212.
go back to reference Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011.
213.
go back to reference Standards of medical care in diabetes--2007. Diabetes Care. 2007;30(Suppl 1):S4-S41. Standards of medical care in diabetes--2007. Diabetes Care. 2007;30(Suppl 1):S4-S41.
Metadata
Title
Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches
Authors
Emaad M. Abdel-Rahman, MD
Lawand Saadulla, MD
W. Brian Reeves, MD
Alaa S. Awad, MD, MSc, FASN
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 4/2012
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-011-1912-5

Other articles of this Issue 4/2012

Journal of General Internal Medicine 4/2012 Go to the issue

Healing Arts: Materia Medica

A Prescription for Song

Clinical Practice: Clinical Images

ST-Segment Elevation and Minimally Reactive Pupils

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.